Sign In
Buy BSEM
$4.14
-0.0290 (-0.696%)
At Close: Jun 03, 2026
BioStem Announces Notice of Allowance for Two U.S. Patent Applications
07:00am, Monday, 31'st Mar 2025
POMPANO BEACH, Fla., March 31, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental
BioStem Announces Notice of Allowance for Two U.S. Patent Applications
06:58am, Monday, 31'st Mar 2025
Company continues to innovate and strengthen its patent portfolio with 43 issued patents and 26 pending for its advanced wound care technology POMPANO BEACH, Fla., March 31, 2025 – PRISM MediaWire �
BioStem Technologies to Present at the 24th Annual Needham Virtual Healthcare Conference
07:06am, Thursday, 27'th Mar 2025
The presentation will be webcast at 1:30 PM ET on April 10, 2025 POMPANO BEACH, Fla., March 27, 2025 – BioStem Technologies, Inc.
BioStem Technologies to Present at the 24th Annual Needham Virtual Healthcare Conference
07:00am, Thursday, 27'th Mar 2025
POMPANO BEACH, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-
BioStem Technologies: Building On Advanced Wound Care Needs
01:19am, Monday, 17'th Mar 2025
BioStem Technologies' falling share price and rising earnings present a growth opportunity, supported by strong Q4 results, new products, and a potential NASDAQ listing. Q4-2024 revenue expected to ri
Study comparing BioStem's proprietary amnion chorion allograft versus the standard of care aims to demonstrate superior outcomes, further validating its clinical efficacy to support market expansion P
POMPANO BEACH, Fla., Feb. 24, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-d
POMPANO BEACH, Fla., January 13, 2025 – PRISM MediaWire – BioStem Technologies, Inc. (OTC: BSEM) (“BioStem”, “we”, “us”, or “our”), a leading MedTech company focused on the devel
POMPANO BEACH, Fla., Jan. 08, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-d
Study of Vendaje® versus standard of care aims to show superior wound treatment, supporting market expansion POMPANO BEACH, Fla., January 8, 2025 – PRISM MediaWire – BioStem Technologies, Inc.
BioStem Technologies CEO to Present at Biotech Showcase 2025
07:00am, Thursday, 02'nd Jan 2025
POMPANO BEACH, Fla., Jan. 02, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-
BioStem Technologies CEO to Present at Biotech Showcase 2025
06:59am, Thursday, 02'nd Jan 2025
Presentation to be webcast at 2:30 PM PT on Monday, January 13, 2025 POMPANO BEACH, Florida, January 2, 2025 – PRISM MediaWire – BioStem Technologies, Inc.
Kane Biotech Announces Change in US Distribution Partner for revyve™ Antimicrobial Wound Gel
08:30am, Wednesday, 27'th Nov 2024
BioStem Technologies Signs Letter of Intent to Acquire Exclusive US Distribution Rights for revyve™ from ProgenaCare Global BioStem Technologies Signs Letter of Intent to Acquire Exclusive US Distr
BioStem Announces Notice of Allowance for U.S. Patent Application for Sterile Human Placental Allografts
07:00am, Monday, 25'th Nov 2024
Company continues to advance its placental-derived product portfolio with the first patent granted in the fenestrated wound care market POMPANO BEACH, Fla., Nov. 25, 2024 – PRISM MediaWire – BioS
BioStem Announces Notice of Allowance for U.S. Patent Application for Sterile Human Placental Allografts
07:00am, Monday, 25'th Nov 2024
POMPANO BEACH, Fla., Nov. 25, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-d
